A separate look at the Sail collaboration emphasized the size and structure of the economic terms as J&J expands in vivo CAR-T bets. Alongside the $785 million upfront consideration, J&J receives a time-bound exclusive option to acquire Sail for $2.58 billion, combining equity and milestones. The reported structure underscores how dealmakers are seeking control over early platform validation while sharing development risk through staged payments. Sail, created from the merger of Laronde and Senda Biosciences, is led by Flagship Pioneering executives and is positioned around nanoparticle-enabled delivery concepts for immune-mediated indications. For the cell therapy ecosystem, the transaction is another data point on how large pharma is turning platform bets into structured options—potentially changing negotiation dynamics for next-generation in vivo modalities.